APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Condition: MDS Interventions: Drug: APR-246 + azacitidine; Drug: Azacitidine Sponsor: Aprea Therapeutics AB Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Myelodysplastic Syndrome | Research